For over 20 years, Selexis has helped its partners to generate life-saving biologic medicines and vaccines rapidly and cost-effectively. The SUREtechnology Platform™ is being used by global partners, resulting in more than 140 biologic drug candidates in preclinical and clinical development and eight products in commercial manufacturing. Selexis can generate stable and high-expressing (up to 10 g/L in bioreactor*) research cell banks (RCBs) in as little as 8–12 weeks.
JSR Life Sciences provides specialized technology, products, materials, and services to biopharmaceutical companies and life science researchers through the service offerings of its affiliates: Selexis, MBL, Crown and KBI Biopharma. JSR has created a framework that provides a fully integrated drug development process, from discovery through commercial production, that can accelerate development timelines and increase clinical success rates.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.
In 2019, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.
Trust develops when credibility, respect and fairness thrive in a workplace. A culture of trust gives rise to camaraderie and pride. The survey uses 58 closed questions in the Trust-Index employee survey to find out how employees see the following dimensions in their company….
In 2017, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.
The Contract Development Manufacturing Organization of the 21st CenturyCombined Forces to Serve as the Biopharmaceutical Customer- and Patient-Focused CDMO with the Most Robust and Fastest “Gene to GMP” Service Offering in the Industry
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.
